Matthew Strout

Vice President, Business Development

Professional Overview
Matthew Strout is an accomplished business development executive with extensive experience in the biopharmaceutical industry. As the Vice President of Business Development at ArriVent Biopharma, he leverages his strategic acumen and deep industry expertise to drive the company's growth initiatives and commercial success.

Experience Summary

Current Role
As the Vice President of Business Development at ArriVent Biopharma, Matthew is responsible for identifying and evaluating strategic partnerships, in-licensing opportunities, and corporate development activities. He plays a pivotal role in shaping the company's business strategy, managing cross-functional teams, and ensuring the successful execution of complex transactions.

Career Progression
Prior to his current role, Matthew held senior business development positions at Kernal Biologics and AstraZeneca, where he led hematology and rare disease strategy initiatives. As the Executive Director and Head of Strategic Evaluation at Alexion Pharmaceuticals, he was instrumental in driving the company's growth through strategic acquisitions and collaborations. Matthew's diverse experience also includes roles as an Instructor and Associate Research Scientist at the prestigious Yale School of Medicine.

Academic Background
Matthew holds a Bachelor of Science degree from Yale University and a Doctor of Medicine (M.D.) degree from the Yale School of Medicine. His medical training and academic background provide him with a deep understanding of the scientific and clinical aspects of the biopharmaceutical industry, complementing his strong business acumen.

Areas of Expertise

• Strategic business development and corporate development

• Hematology and rare disease strategy

• Mergers, acquisitions, and licensing negotiations

• Cross-functional team leadership and collaboration

• Translating scientific insights into commercial opportunities

Professional Impact
Throughout his career, Matthew has demonstrated his ability to drive significant value for the organizations he has served. At Alexion Pharmaceuticals, he played a key role in the company's successful acquisition of Achillion Pharmaceuticals, expanding its rare disease pipeline. At AstraZeneca, he spearheaded the development and implementation of the company's hematology strategy, positioning it as a leader in the field.

Conclusion
With his exceptional track record, deep industry knowledge, and proven leadership abilities, Matthew Strout is poised to make a lasting impact at ArriVent Biopharma. His dedication to driving innovation and delivering strategic business solutions makes him a valuable asset in the rapidly evolving biopharmaceutical landscape.